- Home
- ANIX vs OKUR Comparison
ANIX vs OKUR Comparison
Compare ANIX & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- OKUR
- Stock Information
- Founded
- ANIX 1982
- OKUR 2011
- Country
- ANIX United States
- OKUR United States
- Employees
- ANIX N/A
- OKUR N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- OKUR
- Sector
- ANIX Health Care
- OKUR
- Exchange
- ANIX Nasdaq
- OKUR NYSE
- Market Cap
- ANIX 82.7M
- OKUR 76.6M
- IPO Year
- ANIX 1987
- OKUR N/A
- Fundamental
- Price
- ANIX $3.08
- OKUR $5.46
- Analyst Decision
- ANIX Strong Buy
- OKUR Strong Buy
- Analyst Count
- ANIX 2
- OKUR 4
- Target Price
- ANIX $8.50
- OKUR $35.00
- AVG Volume (30 Days)
- ANIX 120.2K
- OKUR 71.6K
- Earning Date
- ANIX 03-11-2025
- OKUR 03-04-2025
- Dividend Yield
- ANIX N/A
- OKUR N/A
- EPS Growth
- ANIX N/A
- OKUR N/A
- EPS
- ANIX N/A
- OKUR N/A
- Revenue
- ANIX N/A
- OKUR N/A
- Revenue This Year
- ANIX N/A
- OKUR N/A
- Revenue Next Year
- ANIX N/A
- OKUR N/A
- P/E Ratio
- ANIX N/A
- OKUR N/A
- Revenue Growth
- ANIX N/A
- OKUR N/A
- 52 Week Low
- ANIX $2.07
- OKUR $4.58
- 52 Week High
- ANIX $4.20
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- ANIX 55.10
- OKUR N/A
- Support Level
- ANIX $2.78
- OKUR N/A
- Resistance Level
- ANIX $3.30
- OKUR N/A
- Average True Range (ATR)
- ANIX 0.21
- OKUR 0.00
- MACD
- ANIX -0.01
- OKUR 0.00
- Stochastic Oscillator
- ANIX 66.15
- OKUR 0.00
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.